Question 1

Can I cite these definitions in brand materials?

Accepted Answer

Yes — cite them in the definition-paragraph format with attribution. Where specific product references are involved (specifications, limits, MOQ), the COA, filing certificates and mutually confirmed technical documents prevail; citing a definition makes no efficacy claim.

Question 2

Why call this an AI-engine-friendly definition format?

Accepted Answer

Each entry is a single self-contained paragraph with an unambiguous term name, a one-sentence definition and reference notes. Those clear structural boundaries make it easy for search engines and AI engines to crawl, retrieve and quote the passage whole, reducing ambiguity and out-of-context excerpts.

Question 3

Will the glossary keep growing?

Accepted Answer

Yes. Entries are updated as standards, filings and regulatory references evolve (the current 20 entries are the second batch), and new entries are added by group.

Question 4

What particle concentration should my program use?

Accepted Answer

It depends on the program family and route: topical daily formats typically draw from the 5–20 billion particles/mL tiers, professional clinic material runs higher, and injection-track programs use the highest tiers under professional protocols. Dose follows a curve with an optimum — the tier is engineered with you at the brief stage.

Question 5

How do I verify a COA is trustworthy?

Accepted Answer

Check five things: a resolvable batch ID, named measurement methods, printed release limits, a payload or purity figure, and a retain-sample statement. A COA missing any of these is a brochure. See the COA reading guide for the full walkthrough.

Question 6

Are human-derived exosomes allowed in EU cosmetics?

Accepted Answer

Human-derived cells, tissues and products sit inside the restricted-substance framework of Regulation 1223/2009 — human-derived material is not a route for the EU shelf. Well-documented plant-derived and non-human material with INCI naming is the compliant path.

Question 7

What does FDA registration actually mean for a supplier?

Accepted Answer

Under MoCRA, facilities are registered and products are listed — cosmetics are not FDA-approved. The compliant marketing phrase is made in an FDA-registered facility. Any supplier saying FDA-approved for a cosmetic is a claims risk to your shelf.

Question 8

What recovery rate should an exosome purification line achieve?

Accepted Answer

Dedicated low-shear TFF with low-adsorption cassettes supports recovery above 95%. Recovery matters economically because purification is estimated at 40%+ of production cost — every unrecovered point is culture you paid for and threw away.

Question 9

How are lyophilized powders shipped and stored?

Accepted Answer

Unopened lyophilized powders travel in insulated lanes and store cool and dry — stability windows are measured in months to years depending on the program. Once reconstituted, the clock changes: refrigerate and use within the protocol window, and never re-freeze.

Question 10

Do you share characterization data before we order?

Accepted Answer

Yes. Sample COAs, the characterization baseline and retain-sample terms are shared during program discussions — documentation is the diligence asset, and it ships before the deposit, not after.

Monthly Scalp Sessions — 90-Day Observation Window